IDERA PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;

            Appointment of Certain Officers; Compensatory Arrangements of Certain
            Officers.

As reported on a Form 8-K filed with the Securities and Exchange Commission on November 17, 2020, Idera Pharmaceuticals, Inc. (the "Company") previously announced that R. Clayton Fletcher retired from his role as the Company's Senior Vice President of Business Development and Strategic Planning, effective December 31, 2020.

On December 29, 2020 (the "Effective Date"), Company entered into a consulting services agreement (the "Consulting Agreement") with Mr. Fletcher. The Consulting Agreement terminates one year following the Effective Date and provides for aggregate payments to Mr. Fletcher of up to $180,000, to be paid in equal monthly installments over the term of the Consulting Agreement. The Consulting Agreement also includes confidentiality and non-solicitation restrictions.

The foregoing description of the Consulting Agreement is qualified in its entirety by reference to the Consulting Agreement filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.



Exhibit
 Number                                   Description

  10.1         Consulting Agreement, dated December 29, 2020, between the Company
             and R. Clayton Fletcher.

104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document).

© Edgar Online, source Glimpses